Genprex, Inc. (NASDAQ:GNPX) reported a small insider sale on April 14, 2026, when director Brent M Longnecker sold a total of 18 shares of common stock for approximately $22. The two transactions recorded on the company's Form 4 showed a per-share price of $1.23.
The filing indicates Longnecker sold 8 shares directly and an additional 10 shares indirectly through Longnecker Associates Ltd. After those transactions, Longnecker retains direct ownership of 9,157 shares of Genprex.
Genprex's share price has been under sustained pressure. The stock is trading at $1.28 and has fallen roughly 90% over the past year and nearly 97% in the last six months, underscoring heavy volatility in the company's market value.
Investment research available to subscribers via InvestingPro is cited in regulatory filings as indicating the shares may be undervalued at current levels, though the filing notes that additional detail is available only to subscribers.
Corporate and clinical developments
Alongside the insider disclosure, Genprex announced that research collaborators will present preclinical data on its REQORSA gene therapy at the American Association for Cancer Research Annual Meeting in April 2026. The presentations are slated to focus on the company's lead candidate, quaratusugene ozeplasmid, being evaluated for treatment of non-small cell lung cancer.
Genprex also confirmed a series of intellectual property wins across multiple jurisdictions. The company received patent approvals in Japan and Europe for REQORSA in combination with immunotherapy agents. The Japanese patent covers use of REQORSA with PD-L1 antibodies, while the European patent involves combinations with PD-1 antibodies. Those patents are described as protecting therapeutic combinations that encompass the ongoing Acclaim-3 clinical trial for small cell lung cancer. In addition, Genprex announced an Australian patent approval for the use of REQORSA with PD-L1 antibodies.
Company statements frame these approvals and the upcoming scientific presentations as steps to broaden the global application of its cancer therapy program.
Context and market signals
The director-level sale disclosed in the Form 4 represents a modest transfer of shares relative to the director's remaining stake and to the company's overall share count. Meanwhile, the stock's pronounced decline over recent months is recorded in public trading levels. The patent activity and conference presentations are noted as material corporate developments in the filings.